Evidence Does Not Support Use of Albuterol in Bronchiolitis Patients

Although pediatricians have often used albuterol to manage bronchiolitis in infants and children, the 2014 Clinical Practice Guideline on Bronchiolitis released by the American Academy of Pediatrics strongly recommend against this use. The document includes direction on diagnosis and risk factor assessment, but states that once a diagnosis of bronchiolitis is made, clinicians should not administer albuterol. The recommendation is based on multiple meta-analyses and systematic reviews which collectively demonstrate that when it comes to length of stay, need for hospitalization, and recovery from bronchiolitis, there is no evidence that albuterol is efficacious despite occasionally providing temporary improvements in clinical scores.[1]

In an interview following the release of the guidelines, primary author, Dr. Shawn Ralston, addressed the recommendations from a risk-benefit perspective and stated that “babies get significant tachycardia, irritability, and all of the side effects from albuterol, when only a very small percentage might benefit.”[2]

These recommendations mark a change from the 2006 guidelines which stated that bronchodilators, like albuterol, should not be used routinely and when used should be carefully monitored and only continued if there is an objectively measurable benefit to the patient.[3]
 Due to the long-standing clinical use of albuterol, the new guidelines have caused much discussion on management of bronchiolitis patients, especially among clinicians in the emergency department for the management of the undifferentiated, wheezing child.[4]

The Seattle Children’s Bronchiolitis Pathway is an example of a potential pathway in light of the updated guidelines. It outlines ED Management, Inpatient Management, as well as High Flow Nasal Cannula (HFNC) Management.

Learn about pediatric high velocity therapy best practices

[1] Ralston, Shawn L et al. “Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis.” Pediatrics 2014;134:e1474–e1502. November 2014. http://pediatrics.aappublications.org/content/pediatrics/early/2014/10/21/peds.2014-2742.full.pdf
[2] Quinonez, Ricardo A. and Shawn L. Ralston. “Bronchiolitis: The Rationale Behind the New AAP Guideline.” Medscape. November 13, 2014. https://www.medscape.com/viewarticle/834677_2
[3] Clinical Practice Guideline: Diagnosis and Management of Bronchiolitis. Pediatrics Volume 118, Number 4, October 2006. 1778-1779. http://pediatrics.aappublications.org/content/pediatrics/118/4/1774.full.pdf
[4] Levine, Amy and April Edwards. “Do the AAP’s New Bronchiolitis Guidelines Throw the Baby Out With the Bathwater?” Emergency Physicians Monthly. Jan 30, 2015. http://epmonthly.com/article/do-the-aap-s-new-bronchiolitis-guidelines-throw-the-baby-out-with-the-bathwater/

This webpage contains links to third party abstracts and/or publications. With respect to those materials, please note that Vapotherm’s Hi-VNI® technology is a tool for treating the signs and symptoms of respiratory distress in patients for whom prescribers desire to add heat and moisture to breathing gases. The linked materials may describe certain outcomes in relation to the use of Vapotherm’s Hi-VNI Technology, but individual results may vary. Practitioners should refer to the full indications for use and operating instructions of any products referenced herein before prescribing them.